This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should You Buy Beaten-Down Biotech Stocks & ETFs?
by Neena Mishra
We highlight 4 ETFs that have started rebounding after a brutal sell-off
A Comprehensive Guide to Genomic ETFs
by Zacks Equity Research
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
ETFs Winners of S&P 500's Second Best Week in 2022
by Sanghamitra Saha
The S&P 500 advanced more than 3% on Friday, logging back-to-back days of gains and marking its first weekly advance since late May.
US Stocks Float Higher Ahead Of Q1 Earnings Season
by Daniel Laboe
Market undertones are turning from a mere buy-the-dip rally to demonstrating real breakout internals
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Zacks Market Edge Highlights: ARKK, ARKG, CTRU, QQQM, and XBI
by Zacks Equity Research
Zacks Market Edge Highlights: ARKK, ARKG, CTRU, QQQM, and XBI
Should You Bet on Cathie Wood in 2022?
by Tracey Ryniec
Two of ARK Invest's most popular ETFs were down double digits in 2021. Is it time to buy?
Is ARK's Stellar Run Over? 5 ETF Themes to Follow Cathie Wood
by Sanghamitra Saha
Though Cathie Wood's Ark Investment¿¿¿s star products underperformed in 2021 and may continue to lag the broader market in 2022, Wood's fans may follow these ETF strategies to capitalize on her vision.
How Did Cathie Wood's ARK Invest Perform in 2021?
by Sweta Jaiswal, FRM
Let's take a look at how ARK Invest ETFs performed in 2021.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV